Supplemental Material, Supplementary_Material_revised_Oct.10 - Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis

Mease, Philip J
McInnes, Iain B.
Tam, Lai-Shan
Rajalingam, Raji
Peterson, Steve
Hassan, Fareen
Chakravarty, Soumya D
Contré, Christine
Armstrong, Alison
Boehncke, Wolf-Henning
Ritchlin, Christopher

September 2022

Objective: The IL-23 p19-subunit inhibitor guselkumab has been previously compared with other targ...

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

Eyerich, Kilian
Weisenseel, Peter
Pinter, Andreas
Schäkel, Knut
Asadullah, Khusru
Wegner, Sven
Muñoz-Elias, Ernesto J.
Bartz, Holger
Taut, Friedmann J. H.
Reich, Kristian

September 2021

Background: Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in patients wi...

Efficacy of a second IL-17 inhibitor in patients with psoriasis: a systematic review and meta-analysis - Supplementary

Loft, N (via Mendeley Data)

July 2020

Supplemental material for Efficacy of a second IL-17 inhibitor in patients with psoriasis: a systema...

Supplemental Material, PRISMA_NMA_Checklist - Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis

C. Cameron (6161996)
C. Druchok (6161999)
B. Hutton (3407222)
S. McElligott (6162002)
S. Nair (2497861)
A. Schubert (1703323)
A. Situ (6162005)
A. Varu (6162008)
R. Villacorta (6162011)

April 2019

Supplemental Material, PRISMA_NMA_Checklist for Guselkumab for the Treatment of Moderate-to-Severe P...

Supplementary Material for Shear et al.

Shear, N (via Mendeley Data)

March 2021

Supplemental material for the manuscript, "Comparative Safety and Benefit-Risk Profile of Biologics ...

Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials

Jing Yang
Zongming Wang
Xilin Zhang

January 2020

Background. To investigate the efficacy and safety of guselkumab in the treatment of moderate-to-sev...

Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis.

Mease, Philip
McInnes, Iain B
Tam, Lai-Shan
Rajalingam, Raji
Peterson, Steve
Hassan, Fareen
Chakravarty, Soumya D
Contré, Christine
Armstrong, Alison
Boehncke, Wolf-Henning
Ritchlin, Christopher

September 2022

OBJECTIVE: The interleukin (IL)-23 p19-subunit inhibitor guselkumab has been previously compared wit...

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials

Mio Nakamura (107500)
Katherine Lee (506099)
Caleb Jeon (5145803)
Sahil Sekhon (4810017)
Ladan Afifi (5145842)
Di Yan (75625)
Kristina Lee (4773972)
Tina Bhutani (4773963)

April 2018

Article full text The full text of this article can be found here....

Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis

Mease, Philip J
McInnes, Iain B
Tam, Lai-Shan
Rajalingam, Raji
Peterson, Steve
Hassan, Fareen
Chakravarty, Soumya D
Contré, Christine
Armstrong, Alison
Boehncke, Wolf-Henning
Ritchlin, Christopher

January 2022

Objective: The interleukin (IL)-23 p19-subunit inhibitor guselkumab has been previously compared wit...

Supplementary Material for "Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials"

Spencer, R (via Mendeley Data)

January 2023

Supplementary tables and figures for the paper titled "Comparative efficacy of biologics and or...

Placebo response meta-analysis - supplementary data

Egeberg, A (via Mendeley Data)

February 2019

Supplementary materials for the manuscript "Placebo response in phase 3 trials of systemic therapie...

Supplementary Material 1 - Supplemental material for Elderly Onset Generalized Pustular Psoriasis: A Systematic Review

Mahek Shergill (17374640)
Rochelle F. McAdam (17374643)
Nawar Tarafdar (17374646)
Muskaan Sachdeva (9447619)
Khalad Maliyar (9700378)
Jorge R. Georgakopoulos (12281207)
Asfandyar Mufti (9700375)
Jensen Yeung (5170499)

November 2023

Supplemental material, Supplementary Material 1, for Elderly Onset Generalized Pustular Psoriasis: A...

Supplemental Material - Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data

Jamie L. W. Rhoads (17603501)
William N. Malatestinic (9435331)
Russel Burge (3556160)
Michael L. Ganz (8429814)
Kristina C. Duffin (17603504)

December 2023

Supplemental Material for Factors Associated With Treatment Escalation for Psoriasis: An Analysis of...

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis

Mease, Philip J.
McInnes, Iain B.
Tam, Lai-Shan
Eaton, Kiefer
Peterson, Steve
Schubert, Agata
Chakravarty, Soumya D.
Parackal, Anna
Karyekar, Chetan S.
Nair, Sandhya
Boehncke, Wolf-Henning
Ritchlin, Christopher

May 2021

Objective: The efficacy of the novel interleukin (IL)-23p19 inhibitor guselkumab for psoriatic art...

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis

Coates, L
Ritchlin, CT
Gossec, L
Helliwell, PS
Rahman, P
Kollmeier, AP
Xu, XL
Shawi, M
Karyekar, CS
Contré, C
Noël, W
Sheng, S
Wang, Y
Xu, S
Mease, PJ

January 2022

Objectives: Evaluate the efficacy of guselkumab for the treatment of active psoriatic arthritis (PsA...

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis

Mease, Philip J
McInnes, Iain B.
Tam, Lai-Shan
Rajalingam, Raji
Peterson, Steve
Hassan, Fareen
Chakravarty, Soumya D
Contré, Christine
Armstrong, Alison
Boehncke, Wolf-Henning
Ritchlin, Christopher

September 2022

Objective: The IL-23 p19-subunit inhibitor guselkumab has been previously compared with other targ...

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

Eyerich, Kilian
Weisenseel, Peter
Pinter, Andreas
Schäkel, Knut
Asadullah, Khusru
Wegner, Sven
Muñoz-Elias, Ernesto J.
Bartz, Holger
Taut, Friedmann J. H.
Reich, Kristian

September 2021

Background: Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in patients wi...

Efficacy of a second IL-17 inhibitor in patients with psoriasis: a systematic review and meta-analysis - Supplementary

Loft, N (via Mendeley Data)

July 2020

Supplemental material for Efficacy of a second IL-17 inhibitor in patients with psoriasis: a systema...

Supplemental Material, PRISMA_NMA_Checklist - Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis

C. Cameron (6161996)
C. Druchok (6161999)
B. Hutton (3407222)
S. McElligott (6162002)
S. Nair (2497861)
A. Schubert (1703323)
A. Situ (6162005)
A. Varu (6162008)
R. Villacorta (6162011)

April 2019

Supplemental Material, PRISMA_NMA_Checklist for Guselkumab for the Treatment of Moderate-to-Severe P...

Supplementary Material for Shear et al.

Shear, N (via Mendeley Data)

March 2021

Supplemental material for the manuscript, "Comparative Safety and Benefit-Risk Profile of Biologics ...

Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials

Jing Yang
Zongming Wang
Xilin Zhang

January 2020

Background. To investigate the efficacy and safety of guselkumab in the treatment of moderate-to-sev...

Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis.

Mease, Philip
McInnes, Iain B
Tam, Lai-Shan
Rajalingam, Raji
Peterson, Steve
Hassan, Fareen
Chakravarty, Soumya D
Contré, Christine
Armstrong, Alison
Boehncke, Wolf-Henning
Ritchlin, Christopher

September 2022

OBJECTIVE: The interleukin (IL)-23 p19-subunit inhibitor guselkumab has been previously compared wit...

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials

Mio Nakamura (107500)
Katherine Lee (506099)
Caleb Jeon (5145803)
Sahil Sekhon (4810017)
Ladan Afifi (5145842)
Di Yan (75625)
Kristina Lee (4773972)
Tina Bhutani (4773963)

April 2018

Article full text The full text of this article can be found here....

Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis

Mease, Philip J
McInnes, Iain B
Tam, Lai-Shan
Rajalingam, Raji
Peterson, Steve
Hassan, Fareen
Chakravarty, Soumya D
Contré, Christine
Armstrong, Alison
Boehncke, Wolf-Henning
Ritchlin, Christopher

January 2022

Objective: The interleukin (IL)-23 p19-subunit inhibitor guselkumab has been previously compared wit...

Supplementary Material for "Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials"

Spencer, R (via Mendeley Data)

January 2023

Supplementary tables and figures for the paper titled "Comparative efficacy of biologics and or...

Placebo response meta-analysis - supplementary data

Egeberg, A (via Mendeley Data)

February 2019

Supplementary materials for the manuscript "Placebo response in phase 3 trials of systemic therapie...

Supplementary Material 1 - Supplemental material for Elderly Onset Generalized Pustular Psoriasis: A Systematic Review

Mahek Shergill (17374640)
Rochelle F. McAdam (17374643)
Nawar Tarafdar (17374646)
Muskaan Sachdeva (9447619)
Khalad Maliyar (9700378)
Jorge R. Georgakopoulos (12281207)
Asfandyar Mufti (9700375)
Jensen Yeung (5170499)

November 2023

Supplemental material, Supplementary Material 1, for Elderly Onset Generalized Pustular Psoriasis: A...

Supplemental Material - Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data

Jamie L. W. Rhoads (17603501)
William N. Malatestinic (9435331)
Russel Burge (3556160)
Michael L. Ganz (8429814)
Kristina C. Duffin (17603504)

December 2023

Supplemental Material for Factors Associated With Treatment Escalation for Psoriasis: An Analysis of...

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis

Mease, Philip J.
McInnes, Iain B.
Tam, Lai-Shan
Eaton, Kiefer
Peterson, Steve
Schubert, Agata
Chakravarty, Soumya D.
Parackal, Anna
Karyekar, Chetan S.
Nair, Sandhya
Boehncke, Wolf-Henning
Ritchlin, Christopher

May 2021

Objective: The efficacy of the novel interleukin (IL)-23p19 inhibitor guselkumab for psoriatic art...

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis

Coates, L
Ritchlin, CT
Gossec, L
Helliwell, PS
Rahman, P
Kollmeier, AP
Xu, XL
Shawi, M
Karyekar, CS
Contré, C
Noël, W
Sheng, S
Wang, Y
Xu, S
Mease, PJ

January 2022

Objectives: Evaluate the efficacy of guselkumab for the treatment of active psoriatic arthritis (PsA...

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis

Mease, Philip J
McInnes, Iain B.
Tam, Lai-Shan
Rajalingam, Raji
Peterson, Steve
Hassan, Fareen
Chakravarty, Soumya D
Contré, Christine
Armstrong, Alison
Boehncke, Wolf-Henning
Ritchlin, Christopher

September 2022

Objective: The IL-23 p19-subunit inhibitor guselkumab has been previously compared with other targ...

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

Eyerich, Kilian
Weisenseel, Peter
Pinter, Andreas
Schäkel, Knut
Asadullah, Khusru
Wegner, Sven
Muñoz-Elias, Ernesto J.
Bartz, Holger
Taut, Friedmann J. H.
Reich, Kristian

September 2021

Background: Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in patients wi...

Efficacy of a second IL-17 inhibitor in patients with psoriasis: a systematic review and meta-analysis - Supplementary

Loft, N (via Mendeley Data)

July 2020

Supplemental material for Efficacy of a second IL-17 inhibitor in patients with psoriasis: a systema...

Supplemental Material, Supplementary_Material_revised_Oct.10 - Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis

Abstract

Extracted data

Supplemental Material, Supplementary_Material_revised_Oct.10 - Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis

Abstract

Extracted data

Related items

Related items